MTD vs. PFE: Mettler-Toledo vs. Pfizer Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while PFE is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Pfizer (PFE) is heavily traded at around 33.67M shares per day, whereas Mettler-Toledo (MTD) sees a more moderate 197.80K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Pfizer (PFE) earns 4.47% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.

Both Mettler-Toledo (MTD) at 28.70% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Mettler-Toledo (MTD) at 3.98% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Both Mettler-Toledo (MTD) at 3.88% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Mettler-Toledo (MTD) at 1.10 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but MTD is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Mettler-Toledo (MTD) at 26.06 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Mettler-Toledo (MTD) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both Mettler-Toledo (MTD) at 37.38 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Mettler-Toledo (MTD) at 8.16 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

Valuation Metrics